Identifying off-guideline treatments that may work for advanced cancer
Official title: Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)
Run by Cancer Commons · NCT07343024 · Data updated 2026-11-12
This project tests whether genomic and lab-based functional tests can help doctors choose FDA-approved off-guideline drugs that might work for people with advanced cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Cancer Commons Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | March 30, 2026 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT07343024 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with advanced cancer who have (or will obtain) genomic or functional test results, have an oncologist willing to prescribe identified off-guideline drugs, can arrange payment for those drugs, and can provide informed consent.
✕Probably not a fit
Patients without test results that yield promising off-guideline drugs, whose oncologists decline to prescribe them, who cannot secure payment for treatment, or who do not consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program collects participants' genomic and/or drug sensitivity test (DST) results and the Cancer Commons scientific team reviews those results alongside a targeted literature review to identify promising off-guideline drugs. The team produces a Scientific Report listing candidate treatments and shares it with the participant's oncologist, who decides whether to prescribe one or more off-guideline drugs. If an oncologist prescribes an off-guideline drug, the participant is enrolled and their subsequent treatment outcomes are recorded in the study database. The study compares multiple functional and genomic assays to estimate how accurately each predicts real-world treatment responses.
Why it matters
Potential benefit: If successful, this work could help identify effective off-guideline treatment options for individual patients and speed clinical acceptance of functional testing for treatment selection.
How similar studies have gone: This approach is relatively novel and prior clinical evidence for functional assays guiding off-guideline drug selection is limited and not yet conclusive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant must have a valid genomic or functional test or willing to undergo a new test * Analysis of the participant's test must produce a set of Promising Off-guideline Drug(s) * Oncologist must be willing to administer one or more Promising Off-guideline Drug(s) * The study team must have an approved method of paying for the administered Off-Guideline Drug(s). Health insurance and self-pay are the two most common sources of payment * Participant must sign the Informed Consent Exclusion criteria: * No set of Promising Off-guideline Drug(s) * Oncologist not willing to administer one or more Promising Off-guideline Drug(s) * No approved method of paying for the administered off-guideline Drug(s) * No signed Informed Consent
Where it's running
-
Cancer Commons
Palo Alto, California, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Concise coaching to guide decisions for advanced cancer patients considering palliative procedures
A coaching program delivered by lay providers will test whether it helps adults with advanced cancer make better, patient-aligned decisions about palliative surgeries or similar interventions.
-
Primary Palliative Care: A Feasibility Project for Family Health Units
This feasibility trial tests a GP training program plus a structured 12-week palliative-care visit plan to see if it can be carried out in primary care for adults with advanced illness.
-
Virtual Group Resilient Living for Advanced Cancer
A group-based online program tests whether seven weekly sessions can reduce anxiety and fatigue and improve quality of life for adults with advanced cancer.
-
IV contrast-enhanced CBCT with HyperSight for image guidance in advanced cancer radiotherapy
This study tests whether giving IV contrast during cone-beam CT helps doctors see the tumor better during radiotherapy in people with advanced cancer.
-
Single-session celiac plexus SBRT using a simulation-free adaptive workflow for cancer-related pain
A pilot test to see if a one-day, simulation-free adaptive radiotherapy process can safely deliver celiac plexus SBRT to adults with advanced pancreatic or other cancers.
-
UI-102 in advanced cancers (phase 1/2) first-in-human
A first-in-human study tests UI-102, given to adults with advanced solid tumors to see if it is safe and shows signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.